Riccardo Forte, MD, is a physician in Private Practice, Como, Italy and Lugano, Switzerland.
Giovanni Salti, MD, is a physician in the Aesthetic Medicine Section, Medlight Istituto Medico, Florence, Italy.
Plast Aesthet Nurs (Phila). 2024;44(3):213-219. doi: 10.1097/PSN.0000000000000571. Epub 2024 Jul 3.
Hyaluronic acid (HA)-based injectables continue to grow in popularity and are used worldwide to improve facial changes associated with aging. Profhilo® Structura (IBSA Farmaceutici Italia, Lodi, Italy) is a novel HA-based product that uses nano hybrid complex of hyaluronic acid (NAHYCO)® technology to create hybrid cooperative complexes consisting of high and low molecular weight HA. Profhilo® Structura's high concentration (45 mg of total HA) and rheological properties (ie, viscosity [resistance to flow] and elasticity [stickiness]) have been specially formulated to restore facial adipose tissue. Because of their early involvement in the facial aging process, the superficial medial and lateral-temporal cheek fat compartments are good candidates for treatment. However, recommendations and guidelines are necessary to ensure that treatment is safe and effective. Three experts were invited to IBSA Farmaceutici Italia Srl to discuss clinical rationale, optimal injection techniques, and clinical outcomes for treating the superficial medial and lateral-temporal cheek fat compartments with Profhilo® Structura. These techniques were developed using patients presenting with either initial hypotrophy of fat compartments within the preauricular area (ie, sinkers) or jowl sagging due to hypotrophy within the preauricular and zygomatic areas (ie, saggers). Targeting these areas using the optimal injection site can maximize product diffusion and minimize the risk for vascular compromise. Targeting these areas also leads to lateral tightening and lipolifting effects due to adipose tissue restoration. The experts agreed that Profhilo® Structura is currently the first and only HA-based injectable treatment that can integrate and restore the adipose tissue in these affected fat compartments.
透明质酸（HA）基注射剂的应用日益普及，并在全球范围内用于改善与衰老相关的面部变化。Profhilo® Structura（IBSA Farmaceutici Italia，意大利洛迪）是一种新型的 HA 基产品，采用纳米杂合透明质酸（NAHYCO）®技术，形成由高、低分子量 HA 组成的杂合协同复合物。Profhilo® Structura 的高浓度（总 HA 为 45mg）和流变学特性（即粘度[流动性阻力]和弹性[粘性]）经过特殊设计，可恢复面部脂肪组织。由于它们在面部衰老过程中的早期参与，浅表中侧颞颊脂肪隔是治疗的良好候选部位。然而，需要有建议和指南来确保治疗的安全和有效。三位专家应邀到 IBSA Farmaceutici Italia Srl 讨论使用 Profhilo® Structura 治疗浅表中侧颞颊脂肪隔的临床原理、最佳注射技术和临床效果。这些技术是针对出现以下情况的患者开发的：前耳区的脂肪隔初始萎缩（即“下沉者”），或前耳区和颧骨区的脂肪隔萎缩导致的下颌松弛（即“下垂者”）。在前耳和颧骨区域使用最佳注射部位靶向这些区域，可以最大限度地提高产品扩散，最小化血管损伤的风险。靶向这些区域还可以通过脂肪组织恢复，实现侧部收紧和脂肪提升效果。专家们一致认为，Profhilo® Structura 是目前首款且唯一可整合和恢复这些受影响脂肪隔中脂肪组织的 HA 基注射治疗药物。
